Bioinformatics comprehensive analysis confirmed the potential involvement of SLC22A1 in lower-grade glioma progression and prognosis
JING HUI1,2, NANA SUN3, YONG LIU4, CHUNBO YU1,2, YONG KE4, YONG CAO4, ANXIAO YU4, QINGHONG KONG1,2,*, YUN LIU1,2,4,*
1 Guizhou Provincial College-Based Key Lab for Tumor Prevention and Treatment with Distinctive Medicines, Zunyi Medical University, Zunyi, 563000, China
2 College of Basic Medicine, Zunyi Medical University, Zunyi, 563000, China
3 Department of Dermatology, Guizhou Province Cosmetic Plastic Surgery Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, 563000, China
4 School of Forensic Medicine, Zunyi Medical University, Zunyi, 563000, China
* Corresponding Author: QINGHONG KONG. Email: 
; YUN LIU. Email: 
BIOCELL https://doi.org/10.32604/biocell.2024.047122
Received 25 October 2023; Accepted 05 March 2024; Published online 18 April 2024
Abstract
Background: Although it has been established that the human Solute Carrier Family 22 (SLC22) functions as a cationic transporter, influencing cellular biological metabolism by modulating the uptake of various cations, its impact on cancer prognosis remains unclear.
Methods: We conducted a comprehensive analysis utilizing data from The Cancer Genome Atlas (TCGA) and other databases to assess the prognostic value and functional implications across various tumors. Silence of SLC22A1 RNA in glioma U251 cells was performed to access the impact of SLC22A1 on lower-grade glioma (LGG) progression.
Results: Our findings demonstrated a significant correlation between
SLC22A1 expression and the survival time of patients with various cancers (
p < 0.05). Importantly, we found the potential involvement of
SLC22A1 in occurrence and progress of certain cancers, with a pronounced impact on LGG. Further examination of the
SLC22A1-LGG relationship revealed its status as an independent risk factor for LGG, suggesting its potential involvement in regulating diverse immune pathways and metabolic activities. Chinese Glioma Genome Atlas (CGGA) data supported the reliability of the risk score as a prognostic and recurrence indicator, emphasizing the accuracy of the nomograph (1, 3, and 5-year-AUC >0.8). Cell proliferation and clone formation experiment proved that decreased expression of
SLC22A1 in glioma U251 cells inhibited glioma cell growth.
Conclusion: Our findings suggest
SLC22A1 has huge prospects as a promising biomarker and therapeutic target for LGG prognosis.
SLC22A1 has only been proved to support cellular function previously. Our findings demonstrated a robust connection between the tumor microenvironment and functional proteins that maintain basal cell metabolism, which gifts unique tumor immune characteristics of gliomas. Additionally, we provide a highly practical prediction model for estimating the survival rate of LGG patients.
Keywords
SLC22A1; LGG; prognosis; immune; nomogram
Open Access
Login
Register
Submit a Paper
Propose a Special lssue
Download PDF
Downloads
Citation Tools
